Last reviewed · How we verify
hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors
Approved treatments
- Alhemo · Novo Nordisk Inc
Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors patent landscape — cliff calendar, originator estates, attackable patents
- hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors treatment landscape brief
- hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors treatment updates RSS
Frequently asked questions about hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors
What drugs treat hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors?
Tracked treatments include Alhemo.
What is the treatment for hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors?
Standard treatment for hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors includes Alhemo. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors patent cliff · hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors CI report
- Treatment: Alhemo · Novo Nordisk Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing